Fracture rates and economic outcomes in patients with osteoporosis prescribed risedronate gastro-resistant versus other oral bisphosphonates: a claims data analysis

SUMMARY: Patients with osteoporosis prescribed risedronate gastro-resistant had a lower incidence of fractures versus those prescribed other oral bisphosphonates. Administration of risedronate gastric-resistant does not require fasting, and this more convenient dosing administration may explain its...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomasius, Friederike, Palacios, Santiago, Alam, Asif, Boolell, Mitra, Vekeman, Francis, Gauthier, Geneviève
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758602/
https://www.ncbi.nlm.nih.gov/pubmed/34490504
http://dx.doi.org/10.1007/s00198-021-06108-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758602/
https://www.ncbi.nlm.nih.gov/pubmed/34490504
http://dx.doi.org/10.1007/s00198-021-06108-w

Ejemplares similares